Search results for: Aceclofenac Acyl-β-D-glucuronide C22H21Cl2NO10 CAS:
#19161652 // To Up
Trace analysis of polar pharmaceuticals in wastewater by LC-MS-MS: comparison of membrane bioreactor and activated sludge systems.
In order to assess the efficiency of wastewater treatment plants in removing pharmaceuticals from wastewater, sensitive and reliable methods are necessary for trace analysis of these micropollutants in the presence of a highly complex matrix. In this study, conventional activated sludge (CAS) and membrane bioreactor (MBR) treatment systems are compared in eliminating pharmaceuticals in wastewater. The pharmaceuticals investigated include aceclofenac, carbamazepine, diclofenac, enalapril, and trimethoprim. Analysis is performed using a liquid chromatograph with hybrid linear ion-trap mass spectrometer equipped with a polar reversed-phase column to achieve good separation and minimize matrix effects. To pre-concentrate the samples, the use of two types of solid-phase extraction packing materials in tandem assures good recoveries of all the target analytes. In the influent, the concentration of these compounds ranges from 0.09 to 1.4 microg/L. Diclofenac shows resistance to degradation in the CAS but is amenable to degradation in the MBR. Trimethoprim and enalapril are only slightly eliminated in the CAS but are reduced by more than 95% in the MBR. Carbamazepine removal is negligible, while aceclofenac is only 50% reduced in CAS and MBR. In general, these results indicate that MBR has a higher efficiency in removing some polar pharmaceuticals in wastewater.Mary Dawn Celiz, Sandra Pérez, Damià Barceló, Diana S Aga
1504 related Products with: Trace analysis of polar pharmaceuticals in wastewater by LC-MS-MS: comparison of membrane bioreactor and activated sludge systems.
4 Membranes/Box2000 pcs4 Membranes/Box4 Membranes/Box4 Membranes/Box4 Membranes/Box4 Membranes/Box4 Membranes/Box4 Membranes/Box100μgRelated Pathways
#18821734 2008/09/26 To Up
First evidence for occurrence of hydroxylated human metabolites of diclofenac and aceclofenac in wastewater using QqLIT-MS and QqTOF-MS.
The two nonsteroidal anti-inflammatory drugs diclofenac (DCF) and aceclofenac (ACF) were monitored for the first time together with their major human phase-I metabolites, namely, 4'-hydroxydiclofenac (4'-OH-DCF) and 4'-hydroxyaceclofenac (4'-OH-ACF), in untreated and treated sewage samples, collected from a municipal wastewater treatment plant which operated a continuous activated sludge (CAS) treatment in parallel with membrane bioreactor (MBR) technology. Mean concentrations of DCF and 4'-OH-DCF in the influent samples amounted to 349 and 237 ng/L, respectively, whereas levels of 4'-OH-ACF (average, 59 ng/L) exceeded those of its parent drug approximately 2-fold (31 ng/L). Removal rates of 26 and 56% were achieved for 4'-OH-DCF following CAS and MBR treatment, respectively. The most efficient elimination was observed for 4'-OH-ACF in the MBR with only 4% of the influent concentration remaining in the treated sewage. Biodegradation experiments in batch reactors loaded with mixed liquor demonstrated that ACF underwent rapid ester cleavage to liberate DCF, thus constituting a possible source of DCF release during biological sewage treatment. Studies on the microbial metabolism of DCF (295 Da) in controlled laboratory settings allowed us to identify three novel aerobic biotransformation products. Structure elucidation by means of ultraperformance liquid chromatography-electrospray ionization-hybrid quadrupole-time-of-flight-mass spectrometry in conjunction with H/D-exchange experiments unequivocally identified them as deriving from nitrosation of the hydroxyl group in the carboxylic acid moiety (324 Da) and from nitration of one of the aromatic ring systems (340 Da). A third microbial metabolite emerging in the test medium was assigned as dichlorobenzoic acid (190 Da), possibly formed by N-dealkylation of DCF and subsequent carboxylation. Taken together, this work constitutes the first report on the occurrence of ACF and the human metabolites 4'-OH-DCF and 4'-OH-ACF in wastewater, underpinning the need of incorporating metabolites excreted by humans in monitoring surveys as part of a risk evaluation for environmentally relevant pharmaceuticals.Sandra Pérez, Damià Barceló
1674 related Products with: First evidence for occurrence of hydroxylated human metabolites of diclofenac and aceclofenac in wastewater using QqLIT-MS and QqTOF-MS.
50 ug100 μg0.1 mg200 1 ml1000 100ul100 μg50ug100 μg 1 GRelated Pathways
#8740087 // To Up
Comparison of the anti-inflammatory effect and gastrointestinal tolerability of aceclofenac and diclofenac.
Aceclofenac (CAS 89796-99-6) and diclofenac (CAS 15307-79-6) are orally effective non-steroidal anti-inflammatory drugs. Their anti-inflammatory and potential gastrointestinal damaging effects were compared following single and repeated administration (5 days). Both drugs exerted an anti-inflammatory activity and showed a similar gastrointestinal tolerability in the rat.A Arañó, M I Zapatero, N Basi, A Duque, S Gropper
1723 related Products with: Comparison of the anti-inflammatory effect and gastrointestinal tolerability of aceclofenac and diclofenac.
100ul1000 100ul0.1 mg1 ml100.00 ul1000 TESTS/0.65ml200 5 G5mg 5 G100ugRelated Pathways
#1815528 // To Up
Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac.
Aceclofenac (2-[(2,6-dichlorophenyl) amine]phenylacetoxyacetic acid; CAS 89796-99-6) is a new orally effective non-steroidal anti-inflammatory agent of the phenylacetic acid group which showed remarkable anti-inflammatory, analgesic, and antipyretic properties. Hence, aceclofenac possesses a potent inhibitory activity in several models of acute and chronic inflammation in rodents, and resembles indometacin and diclofenac in its pharmacodynamic profile, being superior to naproxen and phenylbutazone. In addition, aceclofenac was found to be highly active against sodium urate-induced synovitis in dogs and adjuvant-induced polyarthritis in rats, both prophylactically and therapeutically. The analgesic effect of aceclofenac on the pain elicited by chemical and mechanical stimuli was nearly equal to or slightly better than that of indometacin and diclofenac. Fever induced by brewer's yeast injection in rats was also markedly suppressed by aceclofenac. In contrast, the acute gastric ulcerogenic activity of aceclofenac was about 2, 4 and 7-fold lesser than that of naproxen, diclofenac, or indometacin, respectively. As a consequence of its high anti-inflammatory activity and lower potential for gastric damage aceclofenac exhibited the most favourable therapeutic ratio in comparison with indometacin, diclofenac, naproxen, and phenylbutazone. These data indicate that aceclofenac could be a potent anti-inflammatory and analgesic agent with a wide margin of safety in clinical practice.M Grau, J Guasch, J L Montero, A Felipe, E Carrasco, S Juliá
2233 related Products with: Pharmacology of the potent new non-steroidal anti-inflammatory agent aceclofenac.
200 100.00 ul1 ml100.00 ul0.1 mg100 100.00 ulRelated Pathways
Contact Us:
Belgium
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
[email protected]
France
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
[email protected]
Germany
GENTAUR GmbH
Marienbongard 20
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
[email protected]
United Kingdom
GENTAUR Ltd.
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
[email protected]
Also in
Luxembourg +35220880274
Schweiz Züri +41435006251
Danmark +4569918806
Österreich +43720880899
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
Poland
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
[email protected]
skype gentaurpoland
Nederland
GENTAUR Nederland BV
Kuiper 1
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
[email protected]
Italy
GENTAUR SRL
IVA IT03841300167
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
[email protected]
Spain
GENTAUR Spain
Tel 0911876558
[email protected]
Bulgaria
GENTAUR Bulgaria
53 Iskar Str. 1191 Kokalyane, Sofia
Sofia 1000
Tel 0035924682280
Fax 0035929830072
[email protected]